Published in J Infect Dis on February 01, 1988
Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J Exp Med (1990) 2.33
Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1994) 1.96
A functional tonB gene is required for both utilization of heme and virulence expression by Haemophilus influenzae type b. Infect Immun (1994) 1.81
Recombinant human interleukin-1 induces meningitis and blood-brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J Clin Invest (1991) 1.77
Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev (2002) 1.61
Tumor necrosis factor in mediating experimental Haemophilus influenzae type B meningitis. J Clin Invest (1989) 1.48
Haemophilus influenzae lipopolysaccharide-induced blood brain barrier permeability during experimental meningitis in the rat. J Clin Invest (1988) 1.47
Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev (1993) 1.45
Endotoxin induced damage to the cochlea in guinea pigs. Arch Dis Child (1991) 1.36
Evaluation of CP-99,219, a new fluoroquinolone, for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1995) 1.21
Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy. Infect Immun (1996) 1.19
Effect of mutations in lipooligosaccharide biosynthesis genes on virulence of Haemophilus influenzae type b. Infect Immun (1990) 1.12
Enhanced attenuation of meningeal inflammation and brain edema by concomitant administration of anti-CD18 monoclonal antibodies and dexamethasone in experimental Haemophilus meningitis. J Clin Invest (1991) 1.10
Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis. Antimicrob Agents Chemother (1990) 1.04
Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother (1998) 0.97
Antigenic evidence for simultaneous expression of two different lipooligosaccharides by some strains of Haemophilus influenzae type b. Infect Immun (1989) 0.93
Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 0.90
Haemophilus influenzae porin contributes to signaling of the inflammatory cascade in rat brain. Infect Immun (2001) 0.89
Dexamethasone therapy for bacterial meningitis: Better never than late? Can J Infect Dis (1994) 0.86
Chapter 2: Kill the bacteria...and also their messengers? Adv Immunol (2009) 0.84
The cochlear lesion in experimental bacterial meningitis of the rabbit. Int J Exp Pathol (1995) 0.82
Specific detection of Haemophilus influenzae type b lipooligosaccharide by immunoassay. J Clin Microbiol (1990) 0.80
Should we use dexamethasone in meningitis? The Meningitis Working Party of the British Paediatric Immunology and Infectious Diseases Group. Arch Dis Child (1992) 0.77
Systemic inflammation alters the inflammatory response in experimental lipopolysaccharide-induced meningitis. Clin Exp Immunol (2007) 0.77
Role of glucocorticosteroids in the treatment of infectious diseases. Eur J Clin Microbiol Infect Dis (1993) 0.76
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature (2000) 32.30
Escherichia coli K1 capsular polysaccharide associated with neonatal meningitis. N Engl J Med (1974) 7.89
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med (1994) 6.92
Epidemiology of Escherichia coli K1 in healthy and diseased newborns. Lancet (1975) 6.25
Size heterogeneity of Salmonella typhimurium lipopolysaccharides in outer membranes and culture supernatant membrane fragments. J Bacteriol (1980) 4.84
Anti-endotoxin monoclonal antibodies. N Engl J Med (1992) 4.39
Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N Engl J Med (1988) 4.17
The beneficial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med (1991) 3.94
Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. Ann Emerg Med (1993) 3.67
Dilemmas in diagnosis and management of cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J (1993) 3.38
Identification of immunogenic outer membrane proteins of Haemophilus influenzae type b in the infant rat model system. Infect Immun (1981) 3.37
Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis. J Infect Dis (1981) 3.28
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease. Infect Immun (1982) 3.18
A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group. J Pediatr (1976) 3.13
Group B streptococci: the new challenge in neonatal infections. J Pediatr (1973) 2.90
A diffusible cytotoxin of Haemophilus ducreyi. Proc Natl Acad Sci U S A (1997) 2.89
Antigenic and phenotypic variations of Haemophilus influenzae type b lipopolysaccharide and their relationship to virulence. Infect Immun (1986) 2.84
A minor high-molecular-weight outer membrane protein of Haemophilus influenzae type b is a protective antigen. Infect Immun (1985) 2.81
The spectrum of group B streptococcal infections in infancy. Am J Dis Child (1974) 2.72
Lipopolysaccharide (LPS) partial structures inhibit responses to LPS in a human macrophage cell line without inhibiting LPS uptake by a CD14-mediated pathway. J Exp Med (1992) 2.71
Screening for cephalosporin-resistant Streptococcus pneumoniae with the Kirby-Bauer disk susceptibility test. J Clin Microbiol (1993) 2.69
Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun (2001) 2.68
Relation between Escherichia coli K1 capsular polysaccharide antigen and clinical outcome in neonatal meningitis. Lancet (1974) 2.67
Report of the Task Force on Diagnosis and Management of Meningitis. Pediatrics (1986) 2.62
Evaluation of antimicrobial regimens for treatment of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1993) 2.61
Immunoprotection of rats against Haemophilus influenzae type B disease mediated by monoclonal antibody against a haemophilus outer-membrane protein. Lancet (1982) 2.53
Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg (1988) 2.52
Management of meningitis caused by penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1995) 2.50
Detection of antibody-accessible proteins on the cell surface of Haemophilus influenzae type b. Infect Immun (1981) 2.41
Development of childhood allergy in infants fed breast, soy, or cow milk. J Allergy Clin Immunol (1973) 2.38
Two-dimensional gel electrophoretic comparison of proteins from virulent and avirulent strains of Mycoplasma pneumoniae. Infect Immun (1979) 2.34
Tumor necrosis factor alpha/cachectin and interleukin 1 beta initiate meningeal inflammation. J Exp Med (1990) 2.33
Spread of meningococcal infection within households. Lancet (1974) 2.32
Statins and the acute-phase response. N Engl J Med (2001) 2.28
Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis. Antimicrob Agents Chemother (1980) 2.27
Sepsis neonatorum. N Engl J Med (1981) 2.27
Cerebrospinal fluid evaluation in neonates: comparison of high-risk infants with and without meningitis. J Pediatr (1976) 2.26
Monoclonal antibodies directed against a cell surface-exposed outer membrane protein of Haemophilus influenzae type b. Infect Immun (1982) 2.23
Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics (1989) 2.23
In vitro susceptibility of gram-negative bacilli from pediatric patients to moxalactam, cefotaxime, Ro 13-9904, and other cephalosporins. Antimicrob Agents Chemother (1980) 2.21
Use of polymerase chain reaction and rabbit infectivity testing to detect Treponema pallidum in amniotic fluid, fetal and neonatal sera, and cerebrospinal fluid. J Clin Microbiol (1991) 2.20
Comparative efficacy of ceftriaxone and cefuroxime for treatment of bacterial meningitis. J Pediatr (1989) 2.17
Gram-negative enteric bacillary meningitis: a twenty-one-year experience. J Pediatr (1993) 2.16
Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet (1980) 2.15
Major integral membrane protein immunogens of Treponema pallidum are proteolipids. Infect Immun (1989) 2.15
The rate of bacteriologic response to antimicrobial therapy in neonatal meningitis. Am J Dis Child (1972) 2.13
The UspA1 protein and a second type of UspA2 protein mediate adherence of Moraxella catarrhalis to human epithelial cells in vitro. J Bacteriol (2000) 2.10
A gene cluster involved in the utilization of both free heme and heme:hemopexin by Haemophilus influenzae type b. J Bacteriol (1995) 2.08
Pharmacokinetics and bacteriological efficacy of cefoperazone, ceftriaxone, and moxalactam in experimental Streptococcus pneumoniae and Haemophilus influenzae meningitis. Antimicrob Agents Chemother (1982) 2.08
Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b. Infect Immun (1987) 2.06
Sepsis syndrome and septic shock in pediatrics: current concepts of terminology, pathophysiology, and management. J Pediatr (1993) 2.05
Phenotypic effect of isogenic uspA1 and uspA2 mutations on Moraxella catarrhalis 035E. Infect Immun (1998) 2.03
Isolation of mutants of Mycoplasma pneumoniae defective in hemadsorption. Infect Immun (1979) 2.02
Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides. J Clin Invest (1982) 2.01
Deacylated lipopolysaccharide inhibits neutrophil adherence to endothelium induced by lipopolysaccharide in vitro. J Exp Med (1987) 2.01
Molecular pathophysiology of bacterial meningitis: current concepts and therapeutic implications. J Pediatr (1990) 2.01
Characterization of hemadsorption-negative mutants of Mycoplasma pneumoniae. Infect Immun (1981) 2.00
Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants. J Pediatr (1981) 2.00
Relatively penicillin-resistant pneumococcal infections in pediatric patients. Pediatr Infect Dis (1984) 1.98
Identification of a cytolethal distending toxin gene locus and features of a virulence-associated region in Actinobacillus actinomycetemcomitans. Infect Immun (1999) 1.97
Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun (2001) 1.97
A review: relation between invasiveness and the K1 capsular polysaccharide of Escherichia coli. Pediatr Res (1976) 1.96
Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother (1994) 1.96
A set of two monoclonal antibodies specific for the cell surface-exposed 39K major outer membrane protein of Haemophilus influenzae type b defines all strains of this pathogen. Infect Immun (1983) 1.95
Regional blood flow and oxygen transport in septic shock. Crit Care Med (1993) 1.95
Detoxification of bacterial lipopolysaccharides (endotoxins) by a human neutrophil enzyme. Science (1986) 1.94
A protective epitope of Moraxella catarrhalis is encoded by two different genes. Infect Immun (1997) 1.89
Epidemic disease due to serogroup C Neisseria meningitidis in Saõ Paulo, Brazil. J Infect Dis (1974) 1.85
A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect Immun (1993) 1.84
Coprecipitation of lipopolysaccharide and the 39,000-molecular-weight major outer membrane protein of Haemophilus influenzae type b by lipopolysaccharide-directed monoclonal antibody. Infect Immun (1985) 1.84
Epidemiologic studies of serotype antigens common to groups B and C Neisseria meningitidis. J Infect Dis (1975) 1.84
Characterization of the Moraxella catarrhalis uspA1 and uspA2 genes and their encoded products. J Bacteriol (1999) 1.82
Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey. J Clin Invest (1981) 1.81
A functional tonB gene is required for both utilization of heme and virulence expression by Haemophilus influenzae type b. Infect Immun (1994) 1.81
Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J (1999) 1.81
Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med (1994) 1.80
Identification of a genetic locus of Haemophilus influenzae type b necessary for the binding and utilization of heme bound to human hemopexin. Proc Natl Acad Sci U S A (1992) 1.80
Adverse fetal outcome following maternal rubella after the first trimester of pregnancy. JAMA (1969) 1.78
Single-dose penicillin prophylaxis against neonatal group B streptococcal infections. A controlled trial in 18,738 newborn infants. N Engl J Med (1980) 1.78
A temperature-dependent rabbit model for production of dermal lesions by Haemophilus ducreyi. J Infect Dis (1991) 1.77
Ceftriaxone versus ampicillin and chloramphenicol for treatment of bacterial meningitis in children. Lancet (1983) 1.77
Proposed cutoff values to define bladder outlet obstruction in women. Urology (1998) 1.76
Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr (1980) 1.71
Enzymatic deacylation of the lipid A moiety of Salmonella typhimurium lipopolysaccharides by human neutrophils. Proc Natl Acad Sci U S A (1983) 1.71
Human disease caused by Brucella canis. A clinical and epidemiologic study of two cases. JAMA (1975) 1.69
Leukocyte function and the development of opsonic and complement activity in the neonate. Am J Dis Child (1971) 1.68
Pharmacological basis for antimicrobial therapy in newborn infants. Am J Dis Child (1974) 1.66
Modulation of inflammation and cachectin activity in relation to treatment of experimental Hemophilus influenzae type b meningitis. J Infect Dis (1989) 1.66
Comparative pharmacokinetics of amoxicillin and ampicillin in infants and children. Pediatrics (1979) 1.65
A mutation affecting expression of a major outer membrane protein of Moraxella catarrhalis alters serum resistance and survival in vivo. J Infect Dis (1993) 1.63